id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-E-3269-0005,FDA,FDA-2023-E-3269,Determination of Regulatory Review Period for Purposes of Patent Extension; NEXOBRID,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2024-12-30T17:20:18Z,2024-31022,0,0,0900006486894d0e
FDA-2023-E-3269-0004,FDA,FDA-2023-E-3269,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-27T05:00:00Z,2024,12,2024-12-27T05:00:00Z,,2024-12-27T14:09:04Z,,0,0,090000648689103d
FDA-2023-E-3269-0003,FDA,FDA-2023-E-3269,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-02-05T05:00:00Z,2024,2,2024-02-05T05:00:00Z,,2024-02-05T12:04:27Z,,0,0,09000064863d9a3c